Covid-19 living Data

COVID-19 vaccine effectiveness on variants of concern
(Randomized evidence)

If you want to see all variants, please click here

Alpha

Forest plots
(last update: 2022-04-15)

Description of primary studies

Trial	Type	Comparisons		Design	Participants	Sample size	Overall risk of bias Highest assessment	Full description
		Intervention 1	Intervention 2
Alpha Gamma Delta NCT04646590 Anhui Zhifei Longcom Biopharmaceutical Dai L, N Engl J Med, 2022 Full text Commentary Commentary	Protein subunit	ZF2001	Placebo	RCT Phase 3	Adults 18 years of age or older with no history of Covid-19, positive tests for SARS-CoV-2 exposure or vaccination, or of congenital or acquired immune deficiency or autoimmune disease at 32 clinical centers across Uzbekistan, Indonesia, Pakistan, Ecuador and China.	N=28904	Variant delta: Some concerns Details	Full description
Alpha NCT04611802 Novavax Dunkle L M, N Engl J Med, 2021 Full text Commentary	Protein subunit	NVX-CoV2373	Placebo	RCT Phase 3	Healthy adults in 113 sites in the USA and 6 in Mexico	N=29949	Some concerns Details	Full description
Alpha Delta NCT04641481 Bharat Biotech Ella R, Lancet, 2021 Full text Commentary	Inactivated virus	BBV152	Adjuvant	RCT Phase 3	Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India	N=25798	Variant delta: Some concerns Details Variant alpha: Some concerns Details	Full description
Alpha NCT04400838 AstraZeneca+University of Oxford Emary K, Lancet, 2021 Full text Commentary	Non replicating viral vector	ChAdOx1	MenACWY	RCT Phase 2-3	Adults seronegative at baseline enrolled at 19 study sites in UK	N=10673	Variant alpha: Some concerns Details	Full description
Alpha Beta Gamma Delta NCT04636697 Medicago Inc Hager K, N Engl J Med, 2022 Full text Full text Commentary	Virus-Like particle	CoVLP	Placebo	RCT Phase 3	Adults including elderly with and without comorbidities, with no previous history of virologically confirmed COVID-19, both seronegative and seropositive, at 85 centers in Argentina, Brazil, Canada, Mexico, the UK, and the USA.	N=24141	Variant delta: Some concerns Details	Full description
Alpha NCT04526990 CanSino Biological Inc./Beijing Institute of Biotechnology Halperin SA, Lancet, 2021 Full text Commentary Commentary	Non replicating viral vector	Ad5-nCoV	Adjuvant	RCT Phase 3	Healthy adults with no history of laboratory-confirmed COVID-19 at 66 sites in Argentina, Chile, Mexico, Pakistan, and Russia	N=36982	Some concerns Details	Full description
Alpha NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 ENSEMBLE2 Full text Full text Commentary	Non replicating viral vector	Ad26.COV2.S	Placebo	RCT Phase 3	Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA	N=31835	Some concerns Details	Full description
Alpha Beta Gamma Delta NCT04614948 Janssen Pharmaceutical Companies Hardt K, Lancet Infect Dis, 2022 ENSEMBLE2 Full text Full text Commentary	Non replicating viral vector	Ad26.COV2.S Ad26.COV2.S	Placebo	RCT Phase 3	Adults, healthy or with stable and well-controlled comorbidities, at 125 centers in Belgium, Brazil, Colombia, France, Germany, The Philippines, South Africa, Spain, UK, and USA	N=31835	Some concerns Details	Full description
Alpha NCT04583995; EudraCT 2020-004123-16 Novavax Heath P, Clin Infect Dis, 2022 Full text Commentary	Protein subunit	NVX-CoV2373	Placebo	RCT Phase 3	Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK.	N=15185	Variant alpha: Some concerns Details	Full description
Alpha Beta Delta NCT04649021 Pfizer/BioNTech+Fosun Pharma Hui A-M, Lancet, 2022 Full text Full text Commentary Commentary	RNA based vaccine	BNT162b2	Placebo	RCT Phase 2	Healthy adults and those with a pre-existing stable condition, at 2 centers in China.	N=960	Low Details	Full description
Alpha Beta Delta NCT04900467; EudraCT: 2021-002174-52 Moderna;Pfizer/BioNTech Janssen C, EClinicalMedicine, 2022 Full text Full text Commentary	Heterologous vaccination scheme	BNT/mRNA-1273 m1273/BNT162b2	BNT162b2 mRNA-1273	RCT Phase 2	Adults with no known or suspected history of SARS-CoV-2 infection at 17 centers in France.	N=414	Some concerns Details	Full description
Alpha Gamma NCT04652102; EudraCT 2020-003998-22 CureVac AG Kremsner P, Lancet Infect Dis, 2022 HERALD Full text Commentary	RNA based vaccine	CVnCoV	Placebo	RCT Phase 2-3	Adults with no history of COVID-19 in 47 centers in Belgium, Germany, The Netherlands, Spain, Argentina, Colombia, Dominican Republic, Mexico, Panama and Peru	N=39680	Some concerns Details	Full description
Alpha Beta Delta RPCEC00000347 Instituto Finlay de Vacunas Toledo-Romani ME, Med, 2022 Full text Commentary Commentary Commentary	Protein subunit	SOBERANA 02/SOBERANA plus	Adjuvant	RCT Phase 2b	Healthy adults with no known or suspected history of COVID-19 at 2 centers in Cuba.	N=810	Some concerns Details	Full description